Complete Genomics Unveils Advanced Sequencing Solutions at AMP 2025

Introduction

Complete Genomics, a prominent player in the field of genomic sequencing, has made significant strides in its portfolio aimed at both oncology and infectious diseases. This article delves into the highlights of their recent showcase at the 2025 Association for Molecular Pathology (AMP) Annual Meeting held from November 11 to November 15, 2025, in Boston. With a commitment to pushing the boundaries of clinical research and genomic technology, Complete Genomics puts forth an array of innovative solutions and partnerships that promise to revolutionize the landscape of molecular diagnostics.

Showcase of Innovative Sequencing Technologies

Complete Genomics presented at Booth 1210, demonstrating the DNBSEQ sequencing platforms. These platforms can cater to various applications in clinical research, molecular pathology, and translational science. Integral to their presentation was the DNBSEQ-T1+ system, which initially introduced at the AGBT conference and now operational in the U.S. This system is designed to provide cost-effective and scalable sequencing solutions, accommodating a spectrum of applications such as whole exome studies, oncology, and methylation research.

One of the most notable announcements was the collaboration with SOPHiA GENETICS to integrate Memorial Sloan Kettering Cancer Center's comprehensive genomic profiling assays on the DNBSEQ-T1+ platform. This integration is poised to boost precision oncology capabilities by merging MSK's clinically validated assays with the sophisticated analytics offered by SOPHiA GENETICS and the high-throughput sequencing technology of Complete Genomics. The results from joint validations indicated promising performance improvements, enhancing the overall workflow efficiency for clinical labs and cancer centers.

New Flow Cells for Enhanced Flexibility

The introduction of the new DNBSEQ-G99RS* flow cells was another highlight of the presentation. These flow cells expand the throughput capacity from 40 million to a remarkable 400 million reads per run, thus allowing one instrument to tackle various assays, from infectious diseases to oncology panels, and exome testing. Significantly, this model is the first sequencer manufactured in the U.S. by Complete Genomics, further solidifying their local manufacturing strategy to enhance supply chain efficiency and respond to the growing demands of clinical research.

Innovations in Bioinformatics

In addition to hardware advancements, Complete Genomics revealed the OmicsNest Bioinformatics Analysis Platform designed for streamlined microbial identification and genome assembly. By leveraging Docker-based deployment and seamless integration with ZLIMS/PaaZ and CG instruments, OmicsNest optimizes bioinformatics workflows, enabling rapid insights across a host of microbial applications. This comprehensive platform facilitates an end-to-end solution for diverse sequencing applications, including metagenomics and targeted workflows such as 16S region sequencing.

Workshop Presentations

Complete Genomics, along with partners AccuraGen and ABL Diagnostics, conducted workshops focusing on real-world applications of their genomic technologies. These sessions highlighted advancements in minimal residual disease (MRD) detection techniques and pathogen detection capabilities powered by their DNBSEQ platforms. Notable presentations included applications at the Yale School of Medicine that utilize ultra-sensitive sequencing for monitoring ctDNA in melanoma patients, and analytical validations conducted by Augusta University on a comprehensive oncology panel using DNBSEQ-T1+ and G400 sequencers.

U.S. Manufacturing and Quality Initiatives

Responding to increasing market needs, Complete Genomics has expanded its reagent manufacturing facility in San Jose, California. This expansion aims to bolster the supply of quality reagents for their existing high-throughput sequencers. Moreover, the company completed key audits by TÜV, securing recommendations for ISO 134852026 certification, underscoring their commitment to high-quality standards essential for laboratories in regulated environments.

Conclusion

As Complete Genomics showcases at AMP 2025, it sets a benchmark for innovation within the genomic sequencing domain. With cutting-edge solutions such as DNBSEQ-T1+, physiological insights from OmicsNest, and strategic collaborations bolstered by an expanded U.S. manufacturing footprint, the company is poised for a transformative impact on oncology and infectious disease research methodologies. These advancements not only underscore the potential of genomics in enhancing patient outcomes but also contribute towards a future marked by precision medicine. For comprehensive information, visit Complete Genomics. Note that all DNBSEQ technologies are intended for research use only and are not approved for diagnostic procedures.